Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 400
- Registration Number
- NCT00002822
- Locations
- 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 61
- Registration Number
- NCT00002945
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Combination Chemotherapy in Treating Patients With Lymphoma
- Conditions
- Interventions
- Biological: Filgrastim (G-CSF)Biological: Bleomycin Sulfate (BLM)Biological: Recombinant Interferon AlfaDrug: CarmustineDrug: Cytarabine (ARA-C)Drug: Cisplatin (CDDP)Drug: Etoposide (VP-16)Drug: CyclophosphamideDrug: IfosfamideDrug: IdarubicinDrug: MelphalanDrug: Leucovorin CalciumDrug: mitoxantrone hydrochloride (DHAD)Drug: MethotrexateProcedure: Peripheral Blood Stem Cell TransplantationDrug: MethylprednisoloneDrug: Vincristine SulfateRadiation: Radiation Therapy
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT00002835
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- First Posted Date
- 2003-04-11
- Last Posted Date
- 2013-09-20
- Target Recruit Count
- 750
- Registration Number
- NCT00002701
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇮🇹Federico II University Medical School, Naples (Napoli), Italy
🇮🇹Ospedale S. Gennora USL 42, Naples (Napoli), Italy
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-04-10
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 2000
- Registration Number
- NCT00002658
- Locations
- 🇬🇧
University of Wales College of Medicine, Cardiff, Wales, United Kingdom
Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2003-04-10
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 1000
- Registration Number
- NCT00002653
- Locations
- 🇬🇧
MRC Myelomatosis Trials Office, Birmingham, England, United Kingdom
Stem Cell Transplant to Treat Patients With Systemic Sclerosis
- Conditions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT00058578
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
- Conditions
- Childhood Immunoblastic Large Cell LymphomaChildhood Diffuse Large Cell LymphomaStage I Childhood Small Noncleaved Cell LymphomaStage II Childhood Large Cell LymphomaStage II Childhood Small Noncleaved Cell LymphomaStage IV Childhood Small Noncleaved Cell LymphomaStage I Childhood Large Cell LymphomaStage III Childhood Large Cell LymphomaStage IV Childhood Large Cell LymphomaUntreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- Drug: doxorubicin hydrochlorideDrug: cyclophosphamideDrug: methotrexateDrug: leucovorin calciumDrug: rasburicaseDrug: prednisoneDrug: methylprednisoloneBiological: filgrastimBiological: rituximabDrug: cytarabineDrug: etoposideDrug: vincristine sulfateDrug: hydrocortisone sodium succinateOther: laboratory biomarker analysis
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 97
- Registration Number
- NCT00057811
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT00058422
- Locations
- 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2003-03-28
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 6
- Registration Number
- NCT00057005
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.